TY - JOUR
T1 - Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode
AU - Strakowski, Stephen M.
AU - Johnson, Jacqueline L.
AU - DelBello, Melissa P.
AU - Hamer, Robert M.
AU - Green, Alan I.
AU - Tohen, Mauricio
AU - Lieberman, Jeffrey A.
AU - Glick, Ira
AU - Patel, Jayendra K.
AU - Lieberman, Jeffrey
AU - Perkins, Diana
AU - McEvoy, Joseph Patrick
AU - Charles, Cecil
AU - Keefe, Richard
AU - Zipursky, Robert B.
AU - Daskalakis, Zafiris J.
AU - Green, Alan I.
AU - Nemeroff, Charles B.
AU - Murray, Robin
AU - Sharma, Tonmoy
AU - Gur, Raquel E.
AU - Cohen, Bruce
AU - Centorrino, Franca
AU - Kahn, R. S.
AU - Goodman, Wayne
AU - Kuldau, John
AU - Rothschild, Anthony J.
AU - De Quardo, John
AU - Tollefson, Gary
AU - Sanger, Todd
N1 - Funding Information:
This work was support by an investigator-initiated (JAL) grant from the Eli Lilly Research Foundation.
PY - 2005/10/15
Y1 - 2005/10/15
N2 - Objectives: Schizophrenia causes significant impairments of quality of life. As treatment approaches have advanced, more attention has been given to re-integrating patients into their psychosocial environments, rather than simply monitoring psychotic symptoms. The development of the second-generation antipsychotics raised hope that these medications would provide better quality of life improvement than conventional antipsychotics. This improvement is particularly relevant early in the course of schizophrenia. Methods: To address these considerations, improvements in measures of general health and social function (determined using the SF-36) were assessed in 195 patients with first-episode schizophrenia for up to one year following randomization to either olanzapine or haloperidol in a double blind clinical trial. We hypothesized that olanzapine would demonstrate better improvement on these measures than haloperidol. In order to test this hypothesis, we used a repeated measure model with SF-36 scores as the outcome, and treatment group, time, time2, time-by-treatment group interaction, and time2-by-treatment group interaction as fixed effects. Results: Both treatments demonstrated similar changes on the SF-36. Independent of treatment, patients demonstrated significant improvements in most of the SF-36 subscales, which approached normative scores by the end of one year of treatment. Forty-six of 100 olanzapine-treated patients and 37 of 95 haloperidol-treated patients completed the one year of this study (p < .4). Conclusions: These results suggest an important initial treatment goal for patients with new onset schizophrenic disorders, namely that they can expect to recover significant quality of life and social function at least initially in treatment.
AB - Objectives: Schizophrenia causes significant impairments of quality of life. As treatment approaches have advanced, more attention has been given to re-integrating patients into their psychosocial environments, rather than simply monitoring psychotic symptoms. The development of the second-generation antipsychotics raised hope that these medications would provide better quality of life improvement than conventional antipsychotics. This improvement is particularly relevant early in the course of schizophrenia. Methods: To address these considerations, improvements in measures of general health and social function (determined using the SF-36) were assessed in 195 patients with first-episode schizophrenia for up to one year following randomization to either olanzapine or haloperidol in a double blind clinical trial. We hypothesized that olanzapine would demonstrate better improvement on these measures than haloperidol. In order to test this hypothesis, we used a repeated measure model with SF-36 scores as the outcome, and treatment group, time, time2, time-by-treatment group interaction, and time2-by-treatment group interaction as fixed effects. Results: Both treatments demonstrated similar changes on the SF-36. Independent of treatment, patients demonstrated significant improvements in most of the SF-36 subscales, which approached normative scores by the end of one year of treatment. Forty-six of 100 olanzapine-treated patients and 37 of 95 haloperidol-treated patients completed the one year of this study (p < .4). Conclusions: These results suggest an important initial treatment goal for patients with new onset schizophrenic disorders, namely that they can expect to recover significant quality of life and social function at least initially in treatment.
KW - First-episode psychosis
KW - Functional outcome
KW - SF-26
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=24344477059&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24344477059&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2005.04.017
DO - 10.1016/j.schres.2005.04.017
M3 - Article
C2 - 15950436
AN - SCOPUS:24344477059
SN - 0920-9964
VL - 78
SP - 161
EP - 169
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 2-3
ER -
